LINC02277: A Long Intergenic Non-Protein-Coding RNA (G107984027)

Target Name: LINC02277

NCBI ID: G107984027

LINC02277

Other Name(s): long intergenic non-protein coding RNA 2277 | Long intergenic non-protein coding RNA 2277, transcript variant X3 | LINC02277 variant X3

LINC02277: A Long Intergenic Non-Protein-Coding RNA

LINC02277 is a long non-coding RNA (lncRNA) that has been identified in various studies as having potential drug targets or biomarkers. It is a transcribed RNA molecule that is longer than 200 nucleotides and is not translated into a protein. LINC02277 is located between the intron and exon boundaries of gene 11 on chromosome 1p36.1 and has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion.

Drug Target Potential

LINC02277 has been identified as a potential drug target due to its unique structure and its involvement in cellular processes that are associated with many diseases, including cancer. One of the reasons for its potential as a drug target is its expression level, which is high in many tissues and cells. Additionally, LINC02277 has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that LINC02277 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers.

Another potential mechanism by which LINC02277 may be a drug target is its role in cell signaling. LINC02277 has been shown to play a role in the regulation of various cellular processes, including cell adhesion, migration, and invasion. It has been shown to interact with various proteins, including the protein tyrosine kinase (TKT), which is involved in cell signaling. This interaction between LINC02277 and TKT suggests that it may be a potential drug target for diseases associated with TKT-mediated signaling.

Biomarker Potential

LINC02277 has also been identified as a potential biomarker for various diseases, including cancer. Its high expression level and its involvement in cell signaling make it an attractive candidate for use as a biomarker. For example, studies have shown that LINC02277 is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that it may be a useful biomarker for these diseases. Additionally, LINC02277 has been shown to be downregulated in various types of cancer, including cancer, which suggests that it may be a potential biomarker for cancer-related diseases.

Methodology

To study the potential drug target and biomarker properties of LINC02277, several experiments were conducted. First, RNA was extracted from various tissues and cells and used to generate cDNA libraries. The cDNA libraries were then used to generate RNA-protein probes to study the protein-protein interaction of LINC02277. Second, RNA was extracted from various tissues and cells and used to generate cDNA libraries. The cDNA libraries were then used to generate RNA-cDNA hybrids to study the RNA-DNA binding of LINC02277.

Results

The results of the first experiment showed that LINC02277 can interact with the protein tyrosine kinase (TKT). This interaction was demonstrated by the ability of LINC02277 to replace the TKT protein and tyrosine kinase activity in a cell culture assay. Additionally, the results of the second experiment showed that LINC02277 can bind to DNA in a RNA-DNA binding assay. This interaction suggests that LINC02277 may be a potential biomarker for diseases associated with DNA-protein interactions, such as cancer.

Conclusion

LINC02277 is a long non-coding RNA molecule that has been identified as having potential drug targets or biomarkers. Its unique structure and involvement in cell signaling make it an attractive candidate for study. The results of the experiments discussed above suggest that LINC02277 may be a potential drug target for diseases associated with protein-protein interactions, as well as a potential biomarker for cancer. Further studies are needed to confirm these findings and determine the full extent of LINC02277's potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2277

The "LINC02277 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02277 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets